Gold prices steady with focus on Ukraine-Russia, Jackson Hole
PHILADELPHIA and VANCOUVER, British Columbia - BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW, BCTXZ; TSX: BCT), a clinical-stage biotechnology firm with a market capitalization of $2.5 million, has successfully completed the safety evaluation phase of its Bria-OTS immunotherapy in a Phase 1/2 monotherapy study. According to InvestingPro data, while the company’s stock shows low volatility with a beta of 0.4, it faces financial challenges with negative EBITDA of $4.22 million. The company has now moved on to test the therapy in combination with a checkpoint inhibitor (CPI) in patients with metastatic breast cancer.
The transition to the CPI combination phase follows a three-patient safety run-in with Bria-OTS monotherapy, during which one patient exhibited a complete resolution of lung metastasis. This has set the stage for the current study, which aims to evaluate the potential enhanced anti-tumor effects of Bria-OTS when used together with CPIs.
Dr. Neal S. Chawla, Principal Investigator for the Bria-OTS study, expressed optimism about the combination’s potential, especially for patients who have not seen positive results from current antibody-drug-conjugates or CPIs alone.
BriaCell’s President and CEO, Dr. William V. Williams, highlighted the significance of initiating the CPI combination cohort, viewing it as a step closer to providing personalized immunotherapy for hard-to-treat cancers.
The ongoing study is designed to enroll up to 12 patients and will measure safety and objective response rate (ORR) as primary endpoints. In addition, BriaCell plans to test Bria-OTS+, an optimized version of the immunotherapy platform, across various types of cancer, including breast and prostate cancer.
BriaCell, known for developing innovative immunotherapies, is focused on transforming cancer care. InvestingPro analysis reveals the company maintains a current ratio of 1.15, indicating adequate short-term liquidity, though it’s currently burning through cash reserves. The company’s forward-looking statements, which include the belief that Bria-OTS in combination with a CPI could yield greater anti-tumor activity and the potential of Bria-OTS to fill significant gaps in cancer care, are based on current expectations and are subject to risks and uncertainties. Get access to 8 more exclusive InvestingPro Tips and comprehensive financial metrics to make informed investment decisions.
Investors are cautioned that such forward-looking statements involve risks and uncertainties and are encouraged to review the company’s regulatory filings for a more detailed discussion of risk factors. This news is based on a press release statement from BriaCell Therapeutics Corp.
In other recent news, BriaCell Therapeutics Corp. has reported significant developments in its ongoing research for metastatic breast cancer treatments. The company announced a complete resolution of lung metastasis in a patient using its Bria-OTS therapy during a Phase 1/2a clinical trial. Additionally, BriaCell revealed promising survival data from its Phase 2 study of Bria-IMT combined with checkpoint inhibitors, showing a median overall survival of 17.3 months in hormone receptor-positive patients, surpassing the current standard of care. The Phase 3 trial of Bria-IMT, which is in combination with an immune checkpoint inhibitor, will continue following a positive safety review by the Data Safety Monitoring Board. This trial has been granted Fast Track Designation by the FDA, emphasizing the urgency of developing new treatments. Dr. William V. Williams, BriaCell’s President and CEO, expressed satisfaction with the safety and efficacy data, while Dr. Giuseppe Del Priore, Chief Medical Officer, highlighted the potential of these therapies to address unmet medical needs. The company aims to continue its research to confirm these findings and improve treatment options for patients with metastatic breast cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.